The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG.
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2018
At a glance
- Drugs BCG; Mitumomab
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 23 Jun 2009 Merck KGaA added as trial sponsor, lead trial centre and primary outcome added as reported by ClinicalTrials.gov.
- 30 Oct 2008 Actual end date (1 Oct 2002) added as reported by ClinicalTrials.gov.
- 30 Oct 2008 Actual patient number (338) added as reported by ClinicalTrials.gov.